Cancer and Metastasis Reviews

, Volume 31, Issue 3–4, pp 493–500 | Cite as

Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12

  • Irwin H. Gelman


Scaffolding proteins such as SSeCKS/Gravin/AKAP12 (“AKAP12”) are thought to control oncogenic signaling pathways by regulating key mediators in a spatiotemporal manner. The downregulation of AKAP12 in many human cancers, often associated with promoter hypermethylation, or the loss of its locus at 6q24-25.2, correlates with progression to malignancy and metastasis. The forced re-expression of AKAP12 in cancer cell lines suppresses in vitro parameters of oncogenic growth, invasiveness, and cell motility through its ability to scaffold protein kinase C (PKC), F-actin, cyclins, Src, and phosphoinositides, and possibly through additional scaffolding domains for PKA, calmodulin, β1,4-galactosyltransferase-polypeptide-1, β2-adrenergic receptors, and cAMP-specific 3′,5′-cyclic phosphodiesterase 4D. Moreover, AKAP12 re-expression in tumor models results in metastasis suppression through the inhibition of Src-regulated, VEGF-mediated neovascularization at distal sites. The current review will describe the emerging understanding of how AKAP12 regulates cellular senescence and oncogenic progression at the level of tumor cells and tumor-associated microenvironment via its multiple scaffolding functions.


SSeCKS/AKAP12 Metastasis Neovascularization Microenvironment Src PKC PKA Cyclin 



This work is supported by funding from the NIH (CA94108), DOD (PC074228, PC061246, BC086529) and the Roswell Park Alliance Foundation.


  1. 1.
    Gelman, I. H. (2010). Emerging roles for SSeCKS/Gravin/AKAP12 in the control of cell proliferation, cancer malignancy, and barriergenesis. Genes & Cancer, 1(11), 1147–1156.CrossRefGoogle Scholar
  2. 2.
    Malbon, C. C. (2007). A-kinase anchoring proteins: trafficking in G-protein-coupled receptors and the proteins that regulate receptor biology. Current Opinion in Drug Discovery & Development, 10(5), 573–579.Google Scholar
  3. 3.
    Lee, H. S., Han, J., Bai, H. J., & Kim, K. W. (2009). Brain angiogenesis in developmental and pathological processes: regulation, molecular and cellular communication at the neurovascular interface. FEBS Journal, 276(17), 4622–4635.PubMedCrossRefGoogle Scholar
  4. 4.
    Zan, L., Wu, H., Jiang, J., Zhao, S., Song, Y., Teng, G., et al. (2011). Temporal profile of Src, SSeCKS, and angiogenic factors after focal cerebral ischemia: correlations with angiogenesis and cerebral edema. Neurochemistry International, 58(8), 872–879.PubMedCrossRefGoogle Scholar
  5. 5.
    Gordon, T., Grove, B., Loftus, J. C., O'Toole, T., McMillan, R., Lindstrom, J., et al. (1992). Molecular cloning and prelimnary characteriztion of a novel cytoplasmic antigen recognized by myasthenia gravis sera. Journal of Clinical Investigation, 90, 992–999.PubMedCrossRefGoogle Scholar
  6. 6.
    Sasaki, H., Kunimatsu, M., Funii, Y., Yamakawa, Y., Fukai, I., Kiriyama, M., et al. (2001). Autoantibody to gravin is expressed more strongly in younger and nonthymomatous patients with myasthenia gravis. Surgery Today, 31(11), 1036–1037.PubMedCrossRefGoogle Scholar
  7. 7.
    Lin, X., Tombler, E., Nelson, P. J., Ross, M., & Gelman, I. H. (1996). A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. Journal of Biological Chemistry, 271(45), 28430–28438.PubMedCrossRefGoogle Scholar
  8. 8.
    Chapline, C., Mousseau, B., Ramsay, K., Duddy, S., Li, Y., Kiley, S. C., et al. (1996). Identification of a major protein kinase C-binding protein and substrate in rat embryo fibroblasts—decreased expression in transformed cells. Journal of Biological Chemistry, 271, 6417–6422.PubMedCrossRefGoogle Scholar
  9. 9.
    Nauert, J., Klauck, T., Langeberg, L. K., & Scott, J. D. (1997). Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffolding protein. Current Biology, 7, 52–62.PubMedCrossRefGoogle Scholar
  10. 10.
    Burack, W. R., & Shaw, A. S. (2000). Signal transduction: hanging on a scaffold. Current Opinion in Cell Biology, 12(2), 211–216.PubMedCrossRefGoogle Scholar
  11. 11.
    Johnson, G. (2002). Signal transduction—scaffolding proteins—more than meets the eye. Science, 295(5558), 1249–1250.PubMedCrossRefGoogle Scholar
  12. 12.
    Xia, W., & Gelman, I. H. (2002). Mitogen- and FAK-regulated tyrosine phosphorylation of the SSeCKS scaffolding protein modulates its actin-binding properties. Experimental Cell Research, 277(2), 139–151.PubMedCrossRefGoogle Scholar
  13. 13.
    Yan, X., Walkiewicz, M., Carlson, J., Leiphon, L., & Grove, B. (2009). Gravin dynamics regulates the subcellular distribution of PKA. Experimental Cell Research, 315(7), 1247–1259.PubMedCrossRefGoogle Scholar
  14. 14.
    Gao, S., Wang, H. Y., & Malbon, C. C. (2011). AKAP5 and AKAP12 form homo-oligomers. Journal of Molecular Signaling, 6(1), 3.PubMedCrossRefGoogle Scholar
  15. 15.
    Gao, S., Wang, H. Y., & Malbon, C. C. (2011). AKAP12 and AKAP5 form higher-order hetero-oligomers. Journal of Molecular Signaling, 6(1), 8.PubMedCrossRefGoogle Scholar
  16. 16.
    Guo, L. W., Gao, L., Rothschild, J., Su, B., & Gelman, I. H. (2011). Control of protein kinase C activity, phorbol ester-induced cytoskeletal remodeling, and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12. Journal of Biological Chemistry, 286(44), 38356–38366.PubMedCrossRefGoogle Scholar
  17. 17.
    Lin, X., Nelson, P., & Gelman, I. H. (2000). Regulation of G–> S progression by the SSeCKS tumor suppressor: control of cyclin D expression and cellular compartmentalization. Molecular and Cellular Biology, 20(19), 7259–7272.PubMedCrossRefGoogle Scholar
  18. 18.
    Akakura, S., Huang, C., Nelson, P. J., Foster, B., & Gelman, I. H. (2008). Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia. Cancer Research, 68(13), 5096–5103.PubMedCrossRefGoogle Scholar
  19. 19.
    Kwon, H. B., Choi, Y. K., Lim, J. J., Kwon, S. H., Her, S., Kim, H. J., et al. (2011). AKAP12 regulates vascular integrity in zebrafish. Experimental & Molecular Medicine, 44(3), 225–235.CrossRefGoogle Scholar
  20. 20.
    Gelman, I. H. (2002). The role of the SSeCKS/Gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Frontiers in Bioscience, 7, d1782–d1797.PubMedCrossRefGoogle Scholar
  21. 21.
    Lin, X., & Gelman, I. H. (1997). Re-expression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis. Cancer Research, 57, 2304–2312.PubMedGoogle Scholar
  22. 22.
    Akakura, S., Nochajski, P., Gao, L., Sotomayor, P., Matsui, S., & Gelman, I. H. (2010). Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12. Cell Cycle, 9(23), 4656–4665.PubMedCrossRefGoogle Scholar
  23. 23.
    Weinberg, R. A. (1995). The molecular basis of oncogenes and tumor suppressor genes. Annals of the New York Academy of Science, 758, 331–338.CrossRefGoogle Scholar
  24. 24.
    Xia, W., Unger, P., Miller, L., Nelson, J., & Gelman, I. H. (2001). The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Research, 61(14), 5644–5651.PubMedGoogle Scholar
  25. 25.
    Lapointe, J., Li, C., Giacomini, C. P., Salari, K., Huang, S., Wang, P., et al. (2007). Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Research, 67(18), 8504–8510.PubMedCrossRefGoogle Scholar
  26. 26.
    Streb, J. W., Kitchen, C. M., Gelman, I. H., & Miano, J. M. (2004). Multiple promoters direct expression of three AKAP12 isoforms with distinct subcellular and tissue distribution profiles. Journal of Biological Chemistry, 279(53), 56014–56023.PubMedCrossRefGoogle Scholar
  27. 27.
    Bu, Y., & Gelman, I. H. (2007). v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex. Journal of Biological Chemistry, 282(37), 26725–26739.PubMedCrossRefGoogle Scholar
  28. 28.
    Bu, Y., Gao, L., & Gelman, I. H. (2010). Role for transcription factor TFII-I in the suppression Of SSeCKS/Gravin/Akap12 transcription by Src. International Journal of Cancer, 128(8), 1836–1842.CrossRefGoogle Scholar
  29. 29.
    Choi, M. C., Jong, H. S., Kim, T. Y., Song, S. H., Lee, D. S., Lee, J. W., et al. (2004). AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene, 23(42), 7095–7103.PubMedCrossRefGoogle Scholar
  30. 30.
    Jo, U., Whang, Y. M., Kim, H. K., & Kim, Y. H. (2009). AKAP12alpha is associated with promoter methylation in lung cancer. Cancer Research and Treatment, 38(3), 144–151.CrossRefGoogle Scholar
  31. 31.
    Tessema, M., Willink, R., Do, K., Yu, Y. Y., Yu, W., Machida, E. O., et al. (2008). Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Research, 68(6), 1707–1714.PubMedCrossRefGoogle Scholar
  32. 32.
    Bonazzi, V. F., Irwin, D., & Hayward, N. K. (2009). Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes, Chromosomes & Cancer, 48(1), 10–21.CrossRefGoogle Scholar
  33. 33.
    Mori, Y., Cai, K., Cheng, Y., Wang, S., Paun, B., Hamilton, J. P., et al. (2006). A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology, 131(3), 797–808.PubMedCrossRefGoogle Scholar
  34. 34.
    Liu, W., Guan, M., Su, B., Ye, C., Li, J., Zhang, X., et al. (2010). Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with dukes' stage. Cancer Biology & Therapy, 9(11), 862–871.CrossRefGoogle Scholar
  35. 35.
    Liu, W., Gong, J., Hu, J., Hu, T., Sun, Y., Du, J., et al. (2011). Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score. Urology, 77(4), 1006e1–1006e7.CrossRefGoogle Scholar
  36. 36.
    Wu, W., Zhang, J., Yang, H., Shao, Y., & Yu, B. (2010). Examination of AKAP12 promoter methylation in skin cancer using methylation-sensitive high-resolution melting analysis. Clinical and Experimental Dermatology, 36(4), 381–385.PubMedCrossRefGoogle Scholar
  37. 37.
    Mardin, W., Petrov, K., Enns, A., Senninger, N., Haier, J., & Mees, S. (2010). SERPINB5 and AKAP12—expression and promoter methylation of metastasis suppressor genes in pancreatic ductal adenocarcinoma. BMC Cancer, 10(1), 549.PubMedCrossRefGoogle Scholar
  38. 38.
    Heller, G., Schmidt, W. M., Ziegler, B., Holzer, S., Mullauer, L., Bilban, M., et al. (2008). Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Research, 68(1), 44–54.PubMedCrossRefGoogle Scholar
  39. 39.
    Wang, J., Qin, R., Ma, Y., Wu, H., Peters, H., Tyska, M., et al. (2009). Differential gene expression in normal esophagus and Barrett's esophagus. Journal of Gastroenterology, 44(9), 897–911.PubMedCrossRefGoogle Scholar
  40. 40.
    Jin, Z., Cheng, Y., Gu, W., Zheng, Y., Sato, F., Mori, Y., et al. (2009). A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Research, 69(10), 4112–4115.PubMedCrossRefGoogle Scholar
  41. 41.
    Jin, Z., Hamilton, J. P., Yang, J., Mori, Y., Olaru, A., Sato, F., et al. (2008). Hypermethylation of the AKAP12 promoter is a biomarker of Barrett’s-associated esophageal neoplastic progression. Cancer Epidemiology, Biomarkers & Prevention, 17(1), 111–117.CrossRefGoogle Scholar
  42. 42.
    Cai, Q., Wen, W., Qu, S., Li, G., Egan, K. M., Chen, K., et al. (2011). Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of Chinese, Japanese, and European ancestry. Cancer Research, 71(4), 1344–1355.PubMedCrossRefGoogle Scholar
  43. 43.
    He, M. L., Chen, Y., Chen, Q., He, Y., Zhao, J., Wang, J., et al. (2011). Multiple gene dysfunctions lead to high cancer-susceptibility: evidences from a whole-exome sequencing study. American Journal of Cancer Research, 1(4), 562–573.PubMedGoogle Scholar
  44. 44.
    Hayashi, M., Nomoto, S., Kanda, M., Okamura, Y., Nishikawa, Y., Yamada, S., et al. (2012). Identification of the a kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. Journal of Surgical Oncology, 105(4), 381–386.PubMedCrossRefGoogle Scholar
  45. 45.
    Kim, D. H., Lee, S. T., Won, H. H., Kim, S., Kim, M. J., Kim, H. J., et al. (2011). A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood, 117(25), 6906–6911.PubMedCrossRefGoogle Scholar
  46. 46.
    Daoud, S. S., Munson, P. J., Reinhold, W., Young, L., Prabhu, V. V., Yu, Q., et al. (2003). Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Research, 63(11), 2782–2793.PubMedGoogle Scholar
  47. 47.
    Zhang, X., Ma, L., Enkemann, S. A., & Pledger, W. J. (2003). Role of Gadd45alpha in the density-dependent G1 arrest induced by p27(Kip1). Oncogene, 22(27), 4166–4174.PubMedCrossRefGoogle Scholar
  48. 48.
    Yoo, J. Y., Huso, D. L., Nathans, D., & Desiderio, S. (2002). Specific ablation of Stat3beta distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Cell, 108(3), 331–344.PubMedCrossRefGoogle Scholar
  49. 49.
    Chen, J., Maltby, K. M., & Miano, J. M. (2001). A novel retinoid-response gene set in vascular smooth muscle cells. Biochemistry and Biophysics Research Communications, 281(2), 475–482.CrossRefGoogle Scholar
  50. 50.
    Streb, J. W., Long, X., Lee, T. H., Sun, Q., Kitchen, C. M., Georger, M. A., et al. (2011). Retinoid-induced expression and activity of an immediate early tumor suppressor gene in vascular smooth muscle cells. PLoS One, 6(4), e18538.PubMedCrossRefGoogle Scholar
  51. 51.
    Palmer, H. G., Sanchez-Carbayo, M., Ordonez-Moran, P., Larriba, M. J., Cordon-Cardo, C., & Munoz, A. (2003). Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Research, 63(22), 7799–7806.PubMedGoogle Scholar
  52. 52.
    Kovalenko, P. L., Zhang, Z., Cui, M., Clinton, S. K., & Fleet, J. C. (2010). 1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics, 11, 26.PubMedCrossRefGoogle Scholar
  53. 53.
    Ali, N. A., McKay, M. J., & Molloy, M. P. (2010). Proteomics of Smad4 regulated transforming growth factor-beta signalling in colon cancer cells. Molecular BioSystems, 6(11), 2332–2338.PubMedCrossRefGoogle Scholar
  54. 54.
    Nelson, P., & Gelman, I. H. (1997). Cell-cycle regulated expression and serine phosphorylation of the myristylated protein kinase C substrate, SSeCKS: correlation with cell confluency, G0 phase and serum response. Molecular and Cellular Biochemistry, 175, 233–241.PubMedCrossRefGoogle Scholar
  55. 55.
    Nelson, P. S., Clegg, N., Arnold, H., Ferguson, C., Bonham, M., White, J., et al. (2002). The program of androgen-responsive genes in neoplastic prostate epithelium. Proceedings of the National Academy of Sciences of the United States of America, 99(18), 11890–11895.PubMedCrossRefGoogle Scholar
  56. 56.
    Shao, C., Wang, Y., Yue, H. H., Zhang, Y. T., Shi, C. H., Liu, F., et al. (2007). Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase. Journal of Andrology, 28(6), 804–812.PubMedCrossRefGoogle Scholar
  57. 57.
    Nickols, N. G., & Dervan, P. B. (2007). Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proceedings of the National Academy of Sciences of the United States of America, 104(25), 10418–10423.PubMedCrossRefGoogle Scholar
  58. 58.
    Singh, A. P., Bafna, S., Chaudhary, K., Venkatraman, G., Smith, L., Eudy, J. D., et al. (2008). Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Letters, 259(1), 28–38.PubMedCrossRefGoogle Scholar
  59. 59.
    Cohen, S. B., Waha, A., Gelman, I. H., & Vogt, P. K. (2001). Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10 T1/2 murine fibroblasts. Oncogene, 20(2), 141–146.PubMedCrossRefGoogle Scholar
  60. 60.
    Gelman, I. H., & Gao, L. (2006). The SSeCKS/Gravin/AKAP12 Metastasis Suppressor Inhibits Podosome Formation Via RhoA- and Cdc42-Dependent Pathways. Molecular Cancer Research, 4(3), 151–158.PubMedCrossRefGoogle Scholar
  61. 61.
    Nelson, P. J., Moissoglu, K., Vargas, J. J., Klotman, P. E., & Gelman, I. H. (1999). Involvement of the protein kinase C substrate, SSeCKS, in the actin-based stellate morphology of mesangial cells. Journal of Cell Science, 112(3), 361–370.PubMedGoogle Scholar
  62. 62.
    Lee, S. W., Jung, K. H., Jeong, C. H., Seo, J. H., Yoon, D. K., Suh, J. K., et al. (2011). Inhibition of endothelial cell migration through the downregulation of MMP-9 by A-kinase anchoring protein 12. Molecular Medicine Report, 4(1), 145–149.Google Scholar
  63. 63.
    Su, B., Bu, Y., Engelberg, D., & Gelman, I. H. (2010). SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a PKC-RAF/MEK/ERK pathway. Journal of Biological Chemistry, 285(7), 4578–4586.PubMedCrossRefGoogle Scholar
  64. 64.
    B Su, L Gao, F Meng, L-W Guo, J Rothschild & IH Gelman (in press). Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12, Oncogene.Google Scholar
  65. 65.
    Lee, H., Volonte, D., Galbiati, F., Iyengar, P., Lublin, D. M., Bregman, D. B., et al. (2000). Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Molecular Endocrinology, 14(11), 1750–1775.PubMedCrossRefGoogle Scholar
  66. 66.
    Rinker-Schaeffer, C. W., O'Keefe, J. P., Welch, D. R., & Theodorescu, D. (2006). Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clinical Cancer Research, 12(13), 3882–3889.PubMedCrossRefGoogle Scholar
  67. 67.
    Su, B., Zheng, Q., Vaughan, M. M., Bu, Y., & Gelman, I. H. (2006). SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with VEGF inhibition. Cancer Research, 66(11), 5599–5607.PubMedCrossRefGoogle Scholar
  68. 68.
    Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J., & Cheresh, D. A. (1999). Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Molecular Cell, 4(6), 915–924.PubMedCrossRefGoogle Scholar
  69. 69.
    Eliceiri, B. P., Puente, X. S., Hood, J. D., Stupack, D. G., Schlaepfer, D. D., Huang, X. Z. Z., et al. (2002). Src-mediated coupling of focal adhesion kinase to integrin alpha v beta 5 in vascular endothelial growth factor signaling. The Journal of Cell Biology, 157(1), 149–159.PubMedCrossRefGoogle Scholar
  70. 70.
    Weis, S., Cui, J., Barnes, L., & Cheresh, D. (2004). Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. The Journal of Cell Biology, 167(2), 223–229.PubMedCrossRefGoogle Scholar
  71. 71.
    Lee, S. W., Kim, W. J., Choi, Y. K., Song, H. S., Son, M. J., Gelman, I. H., et al. (2003). SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nature Medicine, 9(7), 900–906.PubMedCrossRefGoogle Scholar
  72. 72.
    Adluri, R. S., Thirunavukkarasu, M., Zhan, L., Akita, Y., Samuel, S. M., Otani, H., et al. (2011). Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. Journal of Molecular and Cellular Cardiology, 50(1), 239–247.PubMedCrossRefGoogle Scholar
  73. 73.
    Choi, Y. K., Kim, J. H., Kim, W. J., Lee, H. Y., Park, J. A., Lee, S. W., et al. (2007). AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1alpha. Journal of Neuroscience, 27(16), 4472–4481.PubMedCrossRefGoogle Scholar
  74. 74.
    Choi, Y. K., & Kim, K. W. (2008). AKAP12 in astrocytes induces barrier functions in human endothelial cells through protein kinase Czeta. FEBS Journal, 275(9), 2338–2353.PubMedCrossRefGoogle Scholar
  75. 75.
    Steagall, R. J., Hua, F., Thirunazukarasu, M., Zhan, L., Li, C., Maulik, N., et al. (2010). HspA12B promotes angiogenesis through suppressing AKAP12 and up-regulating VEGF pathway. Angiogenesis, 118, S449.Google Scholar
  76. 76.
    Liu, W., Guan, M., Hu, T., Gu, X., & Lu, Y. (2011). Re-expression of AKAP12 inhibits progression and metastasis potential of colorectal carcinoma in vivo and in vitro. PLoS One, 6(8), e24015.PubMedCrossRefGoogle Scholar
  77. 77.
    Akakura, S., Bouchard, R., Bshara, W., Morrison, C., & Gelman, I. H. (2010). Carcinogen-induced squamous papillomas and oncogenic progression in the absence of the SSeCKS/AKAP12 metastasis suppressor correlates with FAK upregulation. International Journal of Cancer, 129(8), 2025–2031.Google Scholar
  78. 78.
    Ohtani, N., Mann, D. J., & Hara, E. (2009). Cellular senescence: its role in tumor suppression and aging. Cancer Science, 100(5), 792–797.PubMedCrossRefGoogle Scholar
  79. 79.
    McLean, G. W., Brown, K., Arbuckle, M. I., Wyke, A. W., Pikkarainen, T., Ruoslahti, E., et al. (2001). Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis. Cancer Research, 61(23), 8385–8389.PubMedGoogle Scholar
  80. 80.
    Akakura, S., Su, B., Nochajski, P., Foster, B., Huang, C., Nelson, P. J., et al. (2009). SSeCKS/Gravin/AKAP12 suppresses metastasis through tumor- and microenvironment-specific pathways. Clinical & Experimental Metastasis, 26(7), 864(A49).Google Scholar
  81. 81.
    Daigeler, A., Klein-Hitpass, L., Chromik, M. A., Muller, O., Hauser, J., Homann, H. H., et al. (2008). Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures. BMC Cancer, 8, 313.PubMedCrossRefGoogle Scholar
  82. 82.
    Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., et al. (2009). Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Research, 69(7), 3077–3085.PubMedCrossRefGoogle Scholar
  83. 83.
    Radvanyi, L., Singh-Sandhu, D., Gallichan, S., Lovitt, C., Pedyczak, A., Mallo, G., et al. (2005). The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 102(31), 11005–11010.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Cancer GeneticsRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations